Cargando…

BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma

Inhibitors targeting Bruton's tyrosine kinase (BTK) have revolutionized the treatment for various B-cell malignancies but are limited by acquired resistance after prolonged treatment as a result of mutations in BTK. Here, by a combination of structural modeling, in vitro assays, and deep phosph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Hongwei, Zhu, Yutong, Cheng, Yalong, Hou, Junjie, Jin, Fengjiao, Li, Menglin, Jia, Wei, Cheng, Zhenzhen, Xing, Haimei, Liu, Mike, Han, Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636578/ https://www.ncbi.nlm.nih.gov/pubmed/36183831 http://dx.doi.org/10.1016/j.jbc.2022.102555

Ejemplares similares

Responses to the Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines
por: Kozaki, Ryohei, et al.
Publicado: (2018)

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma
por: Ezell, Scott A., et al.
Publicado: (2014)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma
por: Nagel, Daniel, et al.
Publicado: (2015)

Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma in vivo and vitro
por: Huang, Shujuan, et al.
Publicado: (2020)

Differential Evolutionary Wiring of the Tyrosine Kinase Btk
por: Nawaz, Hossain M., et al.
Publicado: (2012)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma
por: Xu, Xin, et al.
Publicado: (2021)

From identification of the BTK kinase to effective management of leukemia
por: Smith, C I E
Publicado: (2017)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
por: Wu, Hong, et al.
Publicado: (2017)

Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma
por: Thomsen, Emil Aagaard, et al.
Publicado: (2020)

BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells
por: Kong, Weibo, et al.
Publicado: (2021)

Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy
por: Zhu, Weiguo, et al.
Publicado: (2022)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
por: Feng, Xiaoyu, et al.
Publicado: (2023)

Protein Kinase D Is Dispensable for Development and Survival of Drosophila melanogaster
por: Maier, Dieter, et al.
Publicado: (2019)

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
por: Wu, Hong, et al.
Publicado: (2014)

The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma
por: Wang, Haoran, et al.
Publicado: (2021)

A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma
por: Sun, Jie, et al.
Publicado: (2016)

The Tyrosine Kinase Btk Regulates the Macrophage Response to Listeria monocytogenes Infection
por: Köprülü, Afitap Derya, et al.
Publicado: (2013)

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate
por: Wang, Qi, et al.
Publicado: (2015)

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
por: Lin, David Y., et al.
Publicado: (2023)

Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition
por: Jiménez, Isabel, et al.
Publicado: (2020)

Effects of BTK signalling in pathogenic microorganism infections
por: Ye, Bingjue, et al.
Publicado: (2019)

P1219: BGB-16673, A BTK DEGRADER, OVERCOMES ON-TARGET RESISTANCE FROM BTK INHIBITORS AND PRESENTS SUSTAINABLE LONG-TERM TUMOR REGRESSION IN LYMPHOMA XENOGRAFT MODELS
por: Wang, Haitao, et al.
Publicado: (2023)

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma
por: Yu, Hui, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
por: Ringheim, Garth E., et al.
Publicado: (2021)

Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center
por: Zhu, Yanan, et al.
Publicado: (2022)

The Metabolism and Immune Environment in Diffuse Large B-Cell Lymphoma
por: Wu, Jianbo, et al.
Publicado: (2023)

Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma
por: Wang, Sicong, et al.
Publicado: (2023)

ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
por: Ghoshdastidar, Krishnarup, et al.
Publicado: (2020)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
por: Luo, Qiuyun, et al.
Publicado: (2020)

Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development
por: Yu, Xin, et al.
Publicado: (2022)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
por: Ariza, Yuko, et al.
Publicado: (2019)

Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
por: Arthur, Rachael, et al.
Publicado: (2020)

Stimulation of the catalytic activity of the tyrosine kinase Btk by the adaptor protein Grb2
por: Nocka, Laura M, et al.
Publicado: (2023)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nqenpvpm2qaeuui532otutco6t